JIANJUN GAO to Antineoplastic Combined Chemotherapy Protocols
This is a "connection" page, showing publications JIANJUN GAO has written about Antineoplastic Combined Chemotherapy Protocols.
Connection Strength
0.419
-
The evolving treatment landscape of advanced urothelial carcinoma. Curr Opin Oncol. 2021 05 01; 33(3):221-230.
Score: 0.159
-
Towards effective adjuvant treatment for urothelial cancer. Lancet Oncol. 2015 Jan; 16(1):9-10.
Score: 0.102
-
Outcomes of patients with intermediate-risk or poor-risk metastatic renal cell carcinoma who received their first cycle of nivolumab and ipilimumab in the hospital because of symptomatic disease: The MD Anderson Cancer Center experience. Int J Cancer. 2021 07 15; 149(2):387-393.
Score: 0.039
-
Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. Nat Med. 2020 12; 26(12):1845-1851.
Score: 0.038
-
Emerging treatments in advanced urothelial cancer. Curr Opin Oncol. 2020 05; 32(3):232-239.
Score: 0.037
-
Interdependent IL-7 and IFN-? signalling in T-cell controls tumour eradication by combined a-CTLA-4+a-PD-1 therapy. Nat Commun. 2016 08 08; 7:12335.
Score: 0.029
-
Optimal Timing of Chemotherapy and Surgery in Patients with Muscle-Invasive Bladder Cancer and Upper Urinary Tract Urothelial Carcinoma. Urol Clin North Am. 2018 May; 45(2):155-167.
Score: 0.008
-
Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities. Proc Natl Acad Sci U S A. 2016 10 18; 113(42):11919-11924.
Score: 0.007